The woman, from Essex, received the six figure sum after she became addicted to the video puzzle game when she was prescribed ...

Though more research is needed to understand who might benefit from GLP-1 agonists for addiction, early studies suggest that the approach holds promise.

Intra-Cellular Therapies’ CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar depression. With its differentiated safety profile ...

A new clinical trial showed promising results in curbing alcohol cravings in individuals with moderate alcohol-use disorder.

“In the brain, GLP-1 receptors act like a stop light and tell certain areas of the brain to stop releasing dopamine ... who took a GLP-1 receptor agonist medication were less likely to be ...

Multiple system atrophy (MSA) is a rare neurological disorder that leads to the progressive deterioration of nerve cells in ...

RAs, originally for diabetes, may impact brain health, finding potential benefits for dementia and addiction but inconsistent results for mood disorders.

Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year ...

Semaglutide, known as Ozempic, may reduce alcohol cravings and consumption, offering new addiction treatment possibilities.